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ABSTRACT:
The polo-like kinase PLK2 has recently been identified as a potential theranostic 
marker in the management of chemotherapy sensitive cancers. The methylation 
status of the PLK2 CpG island varies with sensitivity to paclitaxel and platinum in 
ovarian cancer cell lines. Importantly, extrapolation of these in vitro data to the 
clinical setting confirms that the methylation status of the PLK2 CpG island predicts 
outcomes in patients treated with carboplatin & paclitaxel chemotherapy. A second 
cell cycle regulator, p57Kip2, is also subject to epigenetic silencing in carboplatin 
resistance in vitro and in vivo, emphasising that cell cycle regulators are important 
determinants of sensitivity to chemotherapeutic agents and providing insights into the 
phenomenon of collateral drug sensitivity in oncology. Understanding the mechanistic 
basis and identification of robust biomarkers to predict collateral sensitivity may 
inform optimal use of chemotherapy in patients receiving multiple lines of treatment. 
INTRODUCTION
The Polo Like Kinases (Plk) are a family of 
structurally similar but functionally (relatively) distinct 
mitotic kinases all of which share homology with the 
Drosophila Polo, mutants of which show defects in 
mitosis and meiosis. There are five human Plk which have 
critical roles in regulation of cell cycle and response to 
DNA damage. Whilst there is good experimental evidence 
that Plk1 may function as an oncogene and indeed is a 
leading target for developmental therapeutics in oncology, 
Plk2-Plk5 have properties more consistent with tumour 
suppressor genes [review 1]. Plk2 was initially identified 
as an early response gene in serum-starved cells re-
challenged with serum, hence the original name Serum 
Inducible Kinase (Snk) [2].. Later it was shown that the 
gene is a transcriptional target of p53 and activates a 
G2-M checkpoint [3]. 
PLK2 IS EPIGENETICALLY REGULATED 
IN HAEMATOLOGICAL NEOPLASIA
We used suppression: subtraction PCR to identify 
PLK2 as a gene down-regulated in B lymphomas [4]. 
Remarkably, Plk2 was subject to methylation-dependent 
transcriptional silencing in 100% of Burkitt lymphoma 
(BL) cell lines and a similarly high proportion of primary 
BL. The CpG island was also methylated across the 
spectrum of B cell lymphomas and in a proportion of 
cases of B cell chronic lymphocytic leukemias (B-CLL), 
suggesting that the gene is frequently down-regulated in 
B cell dyscrasias. More recent studies from our groups 
have shown methylation in the PLK2 CpG island in other 
haematological malignancies including multiple myeloma 
[5], acute myeloid leukemia (AML) and myelodysplastic 
syndromes (MDS) [6]. We found that the frequency of 
methylation was higher in MDS than in AML (88.4% 
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vs 68.9%) and also was significantly higher in low and 
intermediate risk MDS compared to higher risk groups 
(p=0.04). Based on these findings we suggested that 
methylation of PLK2 could be another mechanism that 
leads to increased apoptosis that characterizes early stage 
MDS [6]. Another finding in this study was a tendency 
for improved survival for both AML and MDS patients 
who displayed hypermethylation of the PLK2 CpG island, 
suggesting that the gene may have a utility as a prognostic 
biomarker in myeloid malignancies. In multiple myeloma, 
the frequency of aberrant methylation was found to be 
60%, and although no correlation was found between 
PLK2 methylation and MTHFR genotypes, anemia, bone 
disease or advanced stage, a 48% lower risk of death was 
noted for patients with methylated PLK2 CpG island [5].
DYNAMIC EPIGENETIC CHANGES IN THE 
PLK2 CPG ISLAND METHYLATION WITH 
PACLITAXEL SENSITIVITY: A MODEL 
FOR DRUG RESISTANCE IN OVARIAN 
AND OTHER CANCERS?
The taxanes docetaxel and paclitaxel remain key 
chemotherapeutic agents in the treatment of many solid 
tumours, including breast cancer, epithelial ovarian cancer 
(EOC), non-small cell lung cancer and prostate cancer. 
Resistance to chemotherapy including to the taxanes 
remains, however, one of the most important factors 
limiting the ability of oncologists manage neoplastic 
disease long term. Whereas a subset of human tumours 
exhibit clinical hypersensitivity to chemotherapy [7], the 
majority typically respond transiently to cytotoxic drugs 
but ultimately acquire resistance leading to treatment 
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Figure 1: Methylation of Plk2 is associated with resistance to chemotherapy in EOC. Genomic DNA was isolated from 
primary EOC tissue and matched serum. Methylation in the Plk2 CpG island was analysed by MSP as described in Methods. A: MSP 
analysis of Plk2 in tumour tissue from EOC cases at initial presentation; Solid black panel = patients with subsequent relapse; Shaded 
panel = patients who had not relapsed at the time of censor. p value given (Fisher’s Exact test). B: Kaplan-Meier analysis of cases with 
and without Plk2 methylation in tissue at presentation and at relapse as indicated (p = 0.174, Log rank) and C: Kaplan-Meier analysis of 
cases with and without Plk2 methylation in serum at presentation and at relapse as indicated (p = 0.054, Log rank). Note follow-up period 
is censored if the patient is still alive at the time of the assessment. Censored data is indicated by (☐).
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failure and death. The time interval between initial 
response and clinical drug resistance varies widely. For 
example, small cell lung cancer demonstrates remarkable 
sensitivity to cisplatin and etoposide in the majority of 
patients but relapse is inevitable and frequently occurs 
within weeks of stopping chemotherapy. In EOC, the 
majority of cases are initially sensitive to first-line 
chemotherapy typically with carboplatin and paclitaxel, 
but in contrast to small cell lung cancer sensitivity may be 
retained for extended periods of time, with only gradual 
emergence of drug-resistance. It is standard clinical 
practice to re-challenge EOC patients with platinum-based 
chemotherapy if a disease-free interval of > 1 year has 
elapsed since previous exposure to platinum, but there 
are few other clinico-pathological parameters to guide 
the physician in the rational use of chemotherapy at first 
and subsequent relapses, underlining the importance 
of identifying and validating robust biomarkers of drug 
sensitivity / resistance.
An increasing consensus recognizes the importance 
of epigenetics (heritable non-structural changes in gene 
expression), as a major mechanism driving acquired 
resistance to chemotherapy [8]. A popular approach to 
identifying determinants of acquired resistance to anti-
cancer agents is the use of cell lines made relatively 
resistant to cytotoxic drugs in vitro with subsequent 
analysis either via the testing of candidate genes or by 
expression profiling. We derived a series of novel EOC 
cell lines with acquired resistance to paclitaxel and 
carboplatin and showed that resistance to paclitaxel, 
often with cross-resistance to carboplatin, occurred with 
loss of the G2 checkpoint and apoptosis [9] and we asked 
whether this was associated with changes in expression 
of the Polo Like Kinases. Whereas expression of Plk1, 
Plk3 and Plk4 was unchanged, there was clear and 
reproducible down-regulation of Plk2 due to acquired 
methylation in the CpG-island at the 5’ end of the gene. 
Increasing levels of resistance to paclitaxel correlated with 
incrementally decreased expression of Plk2 and increasing 
CpG island methylation. We propose that exposure to 
chemotherapeutic stress induces methylation in the CpG 
island of specific “ resistance” genes and this seeding 
effect leads to increasing methylation as the level of 
resistance increases, a phenomenon previously described 
in cells exposed to 6-mercaptopurine [10]. A study 
by Matthew et al. [11] described an in vivo study that 
considered the influence of hypoxia on chemosensitivity 
in Plk2-deficient tumours. Complete resistance to 
camptothecin was shown which pointed to an interplay 
between Plk2 and tumour micro-environment, whereas 
in the same experiments normoxia was associated with 
increased drug sensitivity. In the same study, it was shown 
that Plk2 can inhibit mTOR signaling under the influence 
of wild-type p53 control.
In clinical cases of EOC, DNA methylation of the 
CpG island in the PLK2 promoter in tumor tissue was 
associated with a higher risk of relapse in patients treated 
post-operatively with carboplatin and paclitaxel and this 
trend was also reflected in the analysis of matched serum 
samples in which detection of methylated PLK2 genomic 
DNA was more frequent in relapsed cases [9], Figure 
1A. Further, we were able to show in the same series that 
for patients for whom methylated PLK2 was detected in 
either or both tumour tissue and matched serum there was 
reduced survival, shown by Kaplan-Meier analysis (Figure 
1B and 1C). Independent evidence of an important role 
for Plk2 as a determinant of chemotherapy sensitivity 
was afforded by a micro-array study which identified 
Plk2 as a down-regulated gene in chemotherapy-resistant 
EOC [12]. Plk2 was also independently identified as a 
critical determinant of clinical sensitivity of B CLL to 
chemotherapy, failure of Plk2 induction by fludarabine 
strongly predicting chemotherapy resistance [13]. 
Interestingly, when A2780 cells with high level resistance 
to paclitaxel were grown in the absence of maintenance 
exposure to the drug, a paclitaxel sensitive population 
re-emerged which re-expressed Plk2 due to loss of 
methylation in the PLK2 CpG island. These proliferated at 
a higher basal rate than the paclitaxel-resistant cells from 
which they derived, an effect phenol-copied (at least in 
part) by ectopic expression of Plk2 [9] and unpublished 
observations). This was to the best of our knowledge the 
first demonstration that specific epigenetic changes are 
reversible when the selective pressure that initiated and 
then sustained evolution of a drug resistant cell population 
is removed. Our observations may partially answer the 
question of why the longer an individual cancer patient 
is not exposed to anti-cancer agents, the higher the 
probability that clinical response will be seen upon re-
challenge with the original chemotherapy (a regular 
management strategy in platinum sensitive EOC and in 
other cancers treated with platinum such as non-small 
cell and small cell lung cancer and mesothelioma). In this 
model, methylation-dependent transcriptional silencing 
of key cell cycle regulators would increase with ongoing 
exposure to cytotoxic drugs and then diminish when 
chemotherapy is stopped. Re-expression of genes such as 
PLK2 and re-emergence of a more rapidly proliferating 
cell population would manifest as clinical relapse but with 
reacquired chemotherapy sensitivity.
A WIDER ROLE FOR CELL CYCLE 
REGULATORS IN DRUG RESISTANCE IN 
OVARIAN CANCER
We have demonstrated a role for down-regulation 
of Plk2 as a pivotal factor underlying platinum / 
taxane resistance in EOC by a series of gene silencing 
experiments [9]. These findings prompt interesting 
questions concerning a possible more general role for 
cell cycle regulators as determinants of chemotherapy 
sensitivity/ resistance, consistent with work by other 
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investigators [14]. Micro-array analysis of our own series 
of novel paclitaxel- and platinum-resistant EOC cell lines 
has revealed that several such genes are down-regulated in 
isogenic paclitaxel-resistant cell lines, including Wee1 and 
p57Kip2. Down-regulation of p57Kip2 results in unopposed 
activity of the cyclin dependent kinases (CDK) and we 
hypothesized that this could confer collateral sensitivity to 
CDK inhibitors. Testing the CDK2 inhibitor seliciclib in 
EOC cell lines confirmed that this is indeed the case [15]. 
These results raise the intriguing possibility that a subset 
of EOC, in which acquired resistance to chemotherapy 
occurs via transcriptional silencing of cell cycle regulatory 
genes such as p57Kip2 are collaterally sensitized to 
pharmacological inhibition of the CDKs. 
COLLATERAL SENSITIVITY OF DRUG 
RESISTANT CELL LINES – ARE THERE 
OPPORTUNITIES FOR RESENSITISATION?
The term “ collateral sensitivity” was first used in the 
field of microbiology to describe the “hypersensitivity” of 
otherwise antibiotic resistant E.coli (reviewed in Hall et al. 
2009). The mechanistic basis underlying this phenomenon 
are varied and complex but nevertheless encompass a wide 
range of important chemotherapeutic drugs (reviewed in 
16]. The concept that acquired resistance to one class 
of agent may confer “collateral sensitivity” to a second 
class of agents is established in the field of oncology and 
has been explored with a number of cytotoxic cancer 
chemotherapeutic agents [17], but has not been widely 
exploited in the clinical setting.. Interestingly, it was 
shown that the collateral sensitivity of nitrogen mustard-
resistant cells to chloroethyl nitrosoureas was attributable 
to the loss of guanine-O6-alkyl transferase activity present 
in the parent line, implying that changes in expression 
of specific genes confer both resistance and collateral 
sensitivity [18]. A study by Nakajima et al. [19] which 
examined two different time exposures of EOC lines to 
paclitaxel demonstrated a relationship between drug 
exposure time and extent of resistance induction, with 
collateral sensitivity to cisplatin. Another study by Xu et 
al. [20] analysed cisplatin-resistant gastric cancer lines 
generated by use of varying concentrations of inducing 
agent. Higher cisplatin-resistance was shown to correlate 
with collateral sensitivity to other platinum compounds, 
doxorubicin, mitomycin C and 5-FU. A variety of 
mechanisms associated with antioxidant and transporter 
genes was proposed by the authors [20]. There are also 
examples of platinum-resistance being associated with 
collateral sensitivity to anti-folate compounds [21].
Mechanistically, collateral sensitivity: resistance has 
been more rigourously tested with new targeted anti-cancer 
agents. Indeed, the literature cites a number of examples 
where new targeted therapy may be used advantageously 
in combination “cocktails”. Raf-1 transformed cells were 
relatively resistant to doxorubicin but collaterally sensitive 
to the Hsp90-targeting compound Geldanamycin [22]. The 
same study showed a combination of Geldanamycin and 
imatinib to be effective in BCR/Abl expressing cells, but 
only at unrealistic dose levels. An intriguing approach 
was to then consider the cell cycle inhibitor flavopiridol 
– which can act as a transcriptional inhibitor (as can the 
CDK inhibitor seliciclib) and could help to overcome 
the block in apoptosis seen in highly over-expressing 
BCR/Abl cells. Indeed, the triple combination of drugs 
enabled sensitization of the resistant cells to the effects 
of Geldanamycin [22]. Increased activation of AKT and /
or a lack of PTEN is associated with tumours with a high 
proliferative response and chemotherapy resistance, but 
may confer sensitivity to mTOR inhibitors (reviewed 
in23]. This is further complicated by the fact that a 
feedback loop in the mTOR pathway leads to suppression 
of AKT and thus mTOR inhibition could actually lead to 
activation of AKT in some cells [24]. The notch3, jagged 
and Wnt genes have been shown to be expressed in serous 
ovarian cancers [25]. It is tempting to speculate that this 
tumour, which is notoriously chemorefractory, may be 
sensitive to specific targeted agents directed against such 
genotypes.
The EGFR directed tyrosine kinase inhibitor 
Gefitinib, whilst showing itself to be an effective therapy 
in the management of NSCLC with activating mutations 
in EGFR, is also associated with the development of 
resistance rendering it ineffective. NSCLC cell lines with 
acquired resistance to Gefitinib expressing reduced EGFR 
were shown to possess collateral sensitivity to TNF-alpha 
[26]. Even with reduced EGFR levels, Gefitinib resistant 
cells responded to TNF-alpha by autophosphorylation of 
EGFR with reduced AKT-phosphorylation.
Our observations, and those of other investigators, 
imply that a potential approach to therapy of solid 
tumours would envisage molecular profiling pre- and 
post-acquisition of clinical drug resistance. Transcriptional 
silencing of one or more key cell cycle regulators such as 
p57Kip2 would support the use of CDK inhibitors. Clearly, 
such an approach requires additional studies to determine 
the specific role of cell cycle regulators as determinants 
of resistance to individual chemotherapeutic agents and 
the effect of their loss, if any, in conferring collateral 
sensitivity to pharmacological inhibitors of the CDKs.
CONCLUSIONS
Since the first description of anticancer drug 
resistance, investigators have identified a multiplicity 
of mechanisms which affect cellular sensitivity both to 
individual agents and more generally.
Alongside efforts to describe the mechanistic basis 
of reduced response to chemotherapy, there is a continuing 
requirement to identify robust biomarkers which predict 
patients at risk of developing chemotherapy resistant 
disease and suggest optimal alternative therapy for them. 
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We have shown that the cell cycle regulators PLK2 and 
p57Kip2 are important determinants and candidate novel 
biomarkers of chemotherapy resistance in ovarian (and 
potentially other) cancers. Our results raise interesting 
considerations into collateral drug sensitivity in 
chemotherapy resistance both in vitro and in the oncology 
clinic.
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